Press Release November 06, 2013

Goodwin Procter Named 2014 Biotechnology Law Firm of the Year in U.S. News

Goodwin Procter LLP, a national Am Law 50 firm, has been named as the 2014 U.S. News-Best Lawyers’ “Law Firm of the Year” for Biotechnology Law. This is the second consecutive year the firm has received this honor.

Each year, the publication recognizes one law firm per legal practice area based on the firm’s performance in client surveys, as well as from feedback from peer attorneys at other firms and information provided to U.S. News-Best Lawyers as part of its annual law firm ranking survey.

With more than 100 experienced life sciences attorneys, Goodwin has one of the leading biotechnology practices in the United States. The firm’s fully integrated practice, including corporate, intellectual property, partnering, regulatory and litigation attorneys, allows it to effectively serve clients at every stage of the company life cycle. Its clients include more than 400 private and public life sciences companies, from start-ups to Fortune 1000 corporations.

“We are excited to be recognized for the second year in a row by this prestigious survey of our clients and peers,” said Mitchell Bloom, Goodwin partner and national co-chair of the firm’s Life Sciences Practice. “We pride ourselves on delivering responsive and practical business advice to our clients, which represent some of the most exciting companies in our industry. Being recognized again in U.S. News-Best Lawyers affirms the breadth and overall strength of our team and their commitment to the success of our clients.”

“We continue to advise clients on the cutting edge of many of the industry’s most transformative deals, including the $10 billion sale of Onyx Pharmaceuticals to Amgen, one of the largest biotech acquisitions of all time,” added Kingsley Taft, national co-chair of the Firm’s Life Science Practice. “In addition, Goodwin advised Moderna Therapeutics in its option agreement with AstraZeneca, which included a record-setting upfront payment, was the winner of LMG Life Sciences Venture Capital Impact Deal of the Year, and represented the underwriters for Intrexon’s $160 million IPO, the largest biotech IPO since 2000 in post-offer market cap.”

Goodwin also advised the issuers on IPOs for bluebird bio, Foundation Medicine, Esperion Therapeutics, Fate Therapeutics, and Omthera Pharmaceuticals, among others, representing total capital raised in excess of $570 million.

The 2014 U.S. News-Best Lawyers “Best Law Firms” survey also ranked Goodwin’s Biotechnology practice in Tier 1 at the national level for the third consecutive year. In total, the firm was ranked in 105 national and metropolitan practice areas in 2014. For the complete list of Goodwin’s recognition in the survey, please click here.

Firms included in the 2014 “Best Law Firms” list are recognized for professional excellence with persistently impressive ratings from clients and peers. Achieving a tiered ranking signals a unique combination of quality law practice and breadth of legal expertise. The 2014 rankings are based on the highest number of participating firms and highest number of client ballots on record. To be eligible for a ranking, a firm must have a lawyer listed in The Best Lawyers in America, which recognizes the top 4 percent of practicing attorneys in the US. Over 12,000 attorneys provided over 330,000 law firm assessments, and almost 7,000 clients provided close to 20,000 evaluations.

About Goodwin Procter 
Goodwin Procter LLP is a leading Global 100 law firm, with offices in Boston, Hong Kong, London, Los Angeles, New York, San Francisco, Silicon Valley and Washington, D.C. The firm provides corporate law and litigation services, with a focus on matters involving real estate, REITs and real estate capital markets; private equity; technology and life sciences companies; financial institutions; intellectual property; products liability and mass torts; and securities litigation and white collar defense. Information may be found at www.goodwinprocter.com. Follow us on Twitter @GoodwinProcter.